{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:43:30Z","timestamp":1791981810078,"version":"4.4.0"},"publisher-location":"Cham","reference-count":123,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319208244","type":"print"},{"value":"9783319208251","type":"electronic"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-20825-1_8","type":"book-chapter","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T14:48:01Z","timestamp":1443192481000},"page":"233-259","source":"Crossref","is-referenced-by-count":107,"title":["Endocannabinoids and Neurodegenerative Disorders: Parkinson\u2019s Disease, Huntington\u2019s Chorea, Alzheimer\u2019s Disease, and Others"],"prefix":"10.1007","author":[{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0304-3940(01)02065-1","volume":"309","author":"ME Abood","year":"2001","unstructured":"Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:197\u2013201","journal-title":"Neurosci Lett"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2012-111862","volume":"30","author":"E Aso","year":"2012","unstructured":"Aso E, Palomer E, Juv\u00e9s S et al (2012) CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A\u03b2PP\/PS1 mice. J Alzheimers Dis 30:439\u2013459","journal-title":"J Alzheimers Dis"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-130137","volume":"35","author":"E Aso","year":"2013","unstructured":"Aso E, Juv\u00e9s S, Maldonado R, Ferrer I (2013) CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A\u03b2PP\/PS1 mice. J Alzheimers Dis 35:847\u2013858","journal-title":"J Alzheimers Dis"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","volume":"11","author":"D Athauda","year":"2014","unstructured":"Athauda D, Foltynie T (2014) The ongoing pursuit of neuroprotective therapies in Parkinson\u2019s disease. Nat Rev Neurol 11:25\u201340","journal-title":"Nat Rev Neurol"},{"key":"8_CR6","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","volume":"23","author":"C Benito","year":"2003","unstructured":"Benito C, Nu\u00f1ez E, Tolon RM et al (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer\u2019s disease brains. J Neurosci 23:11136\u201311141","journal-title":"J Neurosci"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/j.1476-5381.2012.01889.x","volume":"166","author":"C Benito","year":"2012","unstructured":"Benito C, Tolon RM, Castillo AI et al (2012) \u03b2-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR\u03b1, PPAR\u03b3 and TRPV1, but not CB1 or CB2 receptors. Br J Pharmacol 166:1474\u20131489","journal-title":"Br J Pharmacol"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1517\/13543784.2014.905542","volume":"23","author":"C Berk","year":"2014","unstructured":"Berk C, Paul G, Sabbagh M (2014) Investigational drugs in Alzheimer\u2019s disease: current progress. Expert Opin Investig Drugs 23:837\u2013846","journal-title":"Expert Opin Investig Drugs"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanus L, De Petrocellis L et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effects on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845\u2013852","journal-title":"Br J Pharmacol"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Bl\u00e1zquez","year":"2011","unstructured":"Bl\u00e1zquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease. Brain 134:119\u2013136","journal-title":"Brain"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","volume":"32","author":"J Bouchard","year":"2012","unstructured":"Bouchard J, Truong J, Bouchard K et al (2012) Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease. J Neurosci 32:18259\u201318268","journal-title":"J Neurosci"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1124\/mol.65.4.999","volume":"65","author":"EJ Carrier","year":"2004","unstructured":"Carrier EJ, Kearn CS, Barkmeier AJ et al (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65:999\u20131007","journal-title":"Mol Pharmacol"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","volume":"38","author":"CB Carroll","year":"2012","unstructured":"Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP (2012) \u03949-tetrahydrocannabinol (\u03949-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson\u2019s disease. Neuropathol Appl Neurobiol 38:535\u2013547","journal-title":"Neuropathol Appl Neurobiol"},{"key":"8_CR14","first-page":"1","volume":"17","author":"AR Carta","year":"2014","unstructured":"Carta AR, Simuni T (2014) Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson\u2019s disease. Expert Opin Investig Drugs 17:1\u20139","journal-title":"Expert Opin Investig Drugs"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-130050","volume":"35","author":"MJ Casarejos","year":"2013","unstructured":"Casarejos MJ, Perucho J, G\u00f3mez A et al (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35:525\u2013539","journal-title":"J Alzheimers Dis"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.nbd.2009.10.023","volume":"37","author":"A Castillo","year":"2010","unstructured":"Castillo A, Tol\u00f3n MR, Fern\u00e1ndez-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis 37:434\u2013440","journal-title":"Neurobiol Dis"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/01.RES.87.4.323","volume":"87","author":"Y Chen","year":"2000","unstructured":"Chen Y, McCarron RM, Ohara Y et al (2000) Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 87:323\u2013327","journal-title":"Circ Res"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.celrep.2012.09.030","volume":"2","author":"R Chen","year":"2012","unstructured":"Chen R, Zhang J, Wu Y et al (2012) Monoacylglycerol lipase is a therapeutic target for Alzheimer\u2019s disease. Cell Rep 2:1329\u20131339","journal-title":"Cell Rep"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cell.2013.10.042","volume":"155","author":"R Chen","year":"2013","unstructured":"Chen R, Zhang J, Fan N et al (2013) \u03949-THC-Caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 155:1154\u20131165","journal-title":"Cell"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"8257","DOI":"10.1073\/pnas.1400988111","volume":"111","author":"A Chiarlone","year":"2014","unstructured":"Chiarlone A, Bellocchio L, Bl\u00e1zquez C et al (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A 111:8257\u20138262","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ajpath.2012.11.024","volume":"182","author":"IY Choi","year":"2013","unstructured":"Choi IY, Ju C, Anthony Jalin AM et al (2013) Activation of cannabinoid CB2 receptor-mediated AMPK\/CREB pathway reduces cerebral ischemic injury. Am J Pathol 182:928\u2013939","journal-title":"Am J Pathol"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","volume":"187","author":"YC Chung","year":"2011","unstructured":"Chung YC, Bok E, Huh SH et al (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187:6508\u20136517","journal-title":"J Immunol"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"e39186","DOI":"10.1371\/journal.pone.0039186","volume":"7","author":"C D\u2019Addario","year":"2012","unstructured":"D\u2019Addario C, Di Francesco A, Arosio B et al (2012) Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One 7:e39186","journal-title":"PLoS One"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"9537","DOI":"10.1523\/JNEUROSCI.1942-07.2007","volume":"27","author":"S Dirikoc","year":"2007","unstructured":"Dirikoc S, Priola SA, Marella M, Zs\u00fcrger N, Chabry J (2007) Non-psychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27:9537\u20139544","journal-title":"J Neurosci"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jchemneu.2014.06.004","volume":"59\u201360","author":"MJ Dowie","year":"2014","unstructured":"Dowie MJ, Grimsey NL, Hoffman T, Faull RL, Glass M (2014) Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington\u2019s disease brain. J Chem Neuroanat 59\u201360:62\u201371","journal-title":"J Chem Neuroanat"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2011.10.019","volume":"60","author":"JM Duarte","year":"2012","unstructured":"Duarte JM, Ferreira SG, Carvalho RA, Cunha RA, K\u00f6falvi A (2012) CB1 receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus. Neurochem Int 60:1\u20138","journal-title":"Neurochem Int"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0002-9440(10)63558-4","volume":"163","author":"AB El-Remessy","year":"2003","unstructured":"El-Remessy AB, Khalil IE, Matragoon S et al (2003) Neuroprotective effect of (-)\u03949-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 163:1997\u20132008","journal-title":"Am J Pathol"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","volume":"399","author":"G Esposito","year":"2006","unstructured":"Esposito G, De Filippis D, Maiuri MC et al (2006a) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in \u03b2-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 399:91\u201395","journal-title":"Neurosci Lett"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","volume":"84","author":"G Esposito","year":"2006","unstructured":"Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T (2006b) The marijuana component cannabidiol inhibits \u03b2-amyloid-induced tau protein hyperphosphorylation through Wnt\/beta-catenin pathway rescue in PC12 cells. J Mol Med 84:253\u2013258","journal-title":"J Mol Med"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","volume":"151","author":"G Esposito","year":"2007","unstructured":"Esposito G, Scuderi C, Savani C et al (2007) Cannabidiol in vivo blunts \u03b2-amyloid induced neuroinflammation by suppressing IL-1\u03b2 and iNOS expression. Br J Pharmacol 151:1272\u20131279","journal-title":"Br J Pharmacol"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"e28668","DOI":"10.1371\/journal.pone.0028668","volume":"6","author":"G Esposito","year":"2011","unstructured":"Esposito G, Scuderi C, Valenza M et al (2011) Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS One 6:e28668","journal-title":"PLoS One"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1021\/mp060066m","volume":"3","author":"LM Eubanks","year":"2006","unstructured":"Eubanks LM, Rogers CJ, Beuscher AE et al (2006) A molecular link between the active component of marijuana and Alzheimer\u2019s disease pathology. Mol Pharm 3:773\u2013777","journal-title":"Mol Pharm"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/bph.12492","volume":"171","author":"SG Fagan","year":"2014","unstructured":"Fagan SG, Campbell VA (2014) The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol 171:1347\u20131360","journal-title":"Br J Pharmacol"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.neuropharm.2012.05.013","volume":"63","author":"G Fakhfouri","year":"2012","unstructured":"Fakhfouri G, Ahmadiani A, Rahimian R et al (2012) WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway. Neuropharmacology 63:653\u2013666","journal-title":"Neuropharmacology"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","volume":"156","author":"J Fern\u00e1ndez-Ruiz","year":"2009","unstructured":"Fern\u00e1ndez-Ruiz J (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156:1029\u20131040","journal-title":"Br J Pharmacol"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/3-7643-7358-X_5","volume-title":"Cannabinoids as therapeutics (MDT)","author":"J Fern\u00e1ndez-Ruiz","year":"2005","unstructured":"Fern\u00e1ndez-Ruiz J, Gonz\u00e1lez S, Romero J, Ramos JA (2005) Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R (ed) Cannabinoids as therapeutics (MDT). Birkha\u00fcser Verlag, Basel, pp 79\u2013109"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","volume":"28","author":"J Fern\u00e1ndez-Ruiz","year":"2007","unstructured":"Fern\u00e1ndez-Ruiz J, Romero J, Velasco G et al (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28:39\u201345","journal-title":"Trends Pharmacol Sci"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1517\/14728221003709792","volume":"14","author":"J Fern\u00e1ndez-Ruiz","year":"2010","unstructured":"Fern\u00e1ndez-Ruiz J, Garc\u00eda C, Sagredo O, G\u00f3mez-Ruiz M, de Lago E (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14:387\u2013404","journal-title":"Expert Opin Ther Targets"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","volume":"75","author":"J Fern\u00e1ndez-Ruiz","year":"2013","unstructured":"Fern\u00e1ndez-Ruiz J, Sagredo O, Pazos MR et al (2013) Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 75:323\u2013333","journal-title":"Br J Clin Pharmacol"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/acprof:oso\/9780199662685.003.0027","volume-title":"Handbook of cannabis","author":"J Fern\u00e1ndez-Ruiz","year":"2014","unstructured":"Fern\u00e1ndez-Ruiz J, de Lago E, G\u00f3mez-Ruiz M et al (2014) Neurodegenerative disorders other than multiple sclerosis. In: Pertwee RG (ed) Handbook of cannabis. Oxford University Press, Oxford, pp 505\u2013525"},{"key":"8_CR44","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.2174\/0929867321666140303143455","volume":"21","author":"M Fidaleo","year":"2014","unstructured":"Fidaleo M, Fanelli F, Ceru MP, Moreno S (2014) Neuroprotective properties of peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) and its lipid ligands. Curr Med Chem 21:2803\u20132821","journal-title":"Curr Med Chem"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.expneurol.2010.03.021","volume":"224","author":"CJ Fowler","year":"2010","unstructured":"Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A (2010) Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 224:37\u201347","journal-title":"Exp Neurol"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jns.2014.04.034","volume":"342","author":"M Fujii","year":"2014","unstructured":"Fujii M, Sherchan P, Krafft PR et al (2014) Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats. J Neurol Sci 342:101\u2013106","journal-title":"J Neurol Sci"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","volume":"163","author":"C Garc\u00eda","year":"2011","unstructured":"Garc\u00eda C, Palomo-Garo C, Garc\u00eda-Arencibia M, Ramos J, Pertwee R, Fern\u00e1ndez-Ruiz J (2011) Symptom-relieving and neuroprotective effects of the phytocannabinoid \u03949-THCV in animal models of Parkinson\u2019s disease. Br J Pharmacol 163:1495\u20131506","journal-title":"Br J Pharmacol"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2014.12.003","volume":"587","author":"MC Garc\u00eda","year":"2015","unstructured":"Garc\u00eda MC, Cinquina V, Palomo-Garo C, R\u00e1bano A, Fern\u00e1ndez-Ruiz J (2015) Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson\u2019s disease. Neurosci Lett 587:1\u20134","journal-title":"Neurosci Lett"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","volume":"1134","author":"M Garc\u00eda-Arencibia","year":"2007","unstructured":"Garc\u00eda-Arencibia M, Gonz\u00e1lez S, de Lago E et al (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162\u2013170","journal-title":"Brain Res"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/187152709789824642","volume":"8","author":"M Garc\u00eda-Arencibia","year":"2009","unstructured":"Garc\u00eda-Arencibia M, Garc\u00eda C, Fern\u00e1ndez-Ruiz J (2009) Cannabinoids and Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 8:432\u2013439","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"8_CR133","unstructured":"Garc\u00eda-Caldentey J, Trillo P, Ruiz C et al (2015) A double-blind, cross-over, placebo-controlled, phase II trial with Sativex in Huntington\u2019s disease. Submitted. See also https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01502046"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.2174\/09298673113209990112","volume":"20","author":"WJ Geldenhuys","year":"2013","unstructured":"Geldenhuys WJ, Van der Schyf CJ (2013) Rationally designed multi-targeted agents against neurodegenerative diseases. Curr Med Chem 20:1662\u20131672","journal-title":"Curr Med Chem"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97:505\u2013519","journal-title":"Neuroscience"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/glia.21061","volume":"58","author":"O G\u00f3mez","year":"2010","unstructured":"G\u00f3mez O, Ar\u00e9valo-Martin A, Garc\u00eda-Ovejero D et al (2010) The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation. Glia 58:1913\u20131927","journal-title":"Glia"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/j.1476-5381.2011.01414.x","volume":"163","author":"O G\u00f3mez","year":"2011","unstructured":"G\u00f3mez O, Sanchez-Rodriguez A, Le M et al (2011) Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K\/Akt and the mammalian target of rapamycin (mTOR) pathways. Br J Pharmacol 163:1520\u20131532","journal-title":"Br J Pharmacol"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1755-5949.2010.00195.x","volume":"17","author":"A Gowran","year":"2011","unstructured":"Gowran A, Noonan J, Campbell VA (2011) The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 17:637\u2013644","journal-title":"CNS Neurosci Ther"},{"key":"8_CR56","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","volume":"22","author":"P Gubellini","year":"2002","unstructured":"Gubellini P, Picconi B, Bari M et al (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900\u20136907","journal-title":"J Neurosci"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1046\/j.1471-4159.1998.70020671.x","volume":"70","author":"AJ Hampson","year":"1998","unstructured":"Hampson AJ, Bornheim LM, Scanziani M et al (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671\u2013676","journal-title":"J Neurochem"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","volume":"89","author":"T Iuvone","year":"2004","unstructured":"Iuvone T, Esposito G, Esposito R et al (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89:134\u2013141","journal-title":"J Neurochem"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00065.x","volume":"15","author":"T Iuvone","year":"2009","unstructured":"Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L (2009) Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15:65\u201375","journal-title":"CNS Neurosci Ther"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"893516","DOI":"10.1155\/2014\/893516","volume":"2014","author":"J Jia","year":"2014","unstructured":"Jia J, Ma L, Wu M et al (2014) Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor-mediated type 2 NADPH oxidase. Oxid Med Cell Longev 2014:893516","journal-title":"Oxid Med Cell Longev"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.neures.2008.04.011","volume":"61","author":"M Jim\u00e9nez-Del-Rio","year":"2008","unstructured":"Jim\u00e9nez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C (2008) The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson\u2019s disease. Neurosci Res 61:404\u2013411","journal-title":"Neurosci Res"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.neurobiolaging.2011.03.012","volume":"33","author":"K Jung","year":"2012","unstructured":"Jung K, Astarita G, Yasar S et al (2012) An amyloid \u03b242-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer\u2019s disease. Neurobiol Aging 33:1522\u20131532","journal-title":"Neurobiol Aging"},{"key":"8_CR134","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/glia.22560","volume":"61","author":"S Kallendrusch","year":"2013","unstructured":"Kallendrusch S, Kremzow S, Nowicki M et al (2013) The G protein-coupled receptor 55 ligand l-\u03b1-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia 61:1822\u20131831","journal-title":"Glia"},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/14728222.2012.671812","volume":"16","author":"T Karl","year":"2012","unstructured":"Karl T, Cheng D, Garner B, Arnold JC (2012) The therapeutic potential of the endocannabinoid system for Alzheimer\u2019s disease. Expert Opin Ther Targets 16:407\u2013420","journal-title":"Expert Opin Ther Targets"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-0-387-72005-0_43","volume":"601","author":"TW Klein","year":"2007","unstructured":"Klein TW, Newton CA (2007) Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 601:395\u2013413","journal-title":"Adv Exp Med Biol"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","volume":"285","author":"E Kozela","year":"2010","unstructured":"Kozela E, Pietr M, Juknat A et al (2010) Cannabinoids \u03949-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-\u03b2\/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285:1616\u20131626","journal-title":"J Biol Chem"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881110367732","volume":"25","author":"JL Lanciego","year":"2011","unstructured":"Lanciego JL, Barroso-Chinea P, Rico AJ, Conte-Perales L, Call\u00e9n L, Roda E, G\u00f3mez-Bautista V, L\u00f3pez IP, Lluis C, Labandeira-Garc\u00eda JL, Franco R (2011) Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol 25:97\u2013104","journal-title":"J Psychopharmacol"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","volume":"14","author":"I Lastres-Becker","year":"2001","unstructured":"Lastres-Becker I, Cebeira M, de Ceballos M et al (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson\u2019s disease and MPTP-treated marmosets. Eur J Neurosci 14:1827\u20131832","journal-title":"Eur J Neurosci"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","volume":"929","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, Berrendero F, Lucas JJ et al (2002) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington\u2019s disease. Brain Res 929:236\u2013242","journal-title":"Brain Res"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","volume":"19","author":"I Lastres-Becker","year":"2005","unstructured":"Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fern\u00e1ndez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease. Neurobiol Dis 19:96\u2013107","journal-title":"Neurobiol Dis"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94","journal-title":"Transl Psychiatry"},{"key":"8_CR76","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/JAD-140492","volume":"42","author":"I Manuel","year":"2014","unstructured":"Manuel I, de San G, Rom\u00e1n E, Giralt MT, Ferrer I, Rodr\u00edguez-Puertas R (2014) Type-1 cannabinoid receptor activity during Alzheimer\u2019s disease progression. J Alzheimers Dis 42:761\u2013766","journal-title":"J Alzheimers Dis"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1046\/j.0022-3042.2001.00716.x","volume":"80","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448\u2013456","journal-title":"J Neurochem"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"G Marsicano","year":"2003","unstructured":"Marsicano G, Goodenough S, Monory K et al (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84\u201388","journal-title":"Science"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-9-8","volume":"9","author":"AM Mart\u00edn-Moreno","year":"2012","unstructured":"Mart\u00edn-Moreno AM, Brera B, Spuch C et al (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers \u03b2-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9:8","journal-title":"J Neuroinflammation"},{"issue":"129","key":"8_CR80","doi-asserted-by":"crossref","first-page":"re5","DOI":"10.1126\/stke.2002.129.re5","volume":"2002","author":"R Mechoulam","year":"2002","unstructured":"Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE 2002(129):re5","journal-title":"Sci STKE"},{"key":"8_CR81","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1523\/JNEUROSCI.23-16-06470.2003","volume":"23","author":"F Molina-Holgado","year":"2003","unstructured":"Molina-Holgado F, Pinteaux E, Moore JD et al (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 23:6470\u20136474","journal-title":"J Neurosci"},{"key":"8_CR82","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0006-8993(93)90804-V","volume":"622","author":"V Nadler","year":"1993","unstructured":"Nadler V, Mechoulam R, Sokolovsky M (1993) Blockade of 45Ca2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 622:79\u201385","journal-title":"Brain Res"},{"key":"8_CR83","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1523\/JNEUROSCI.19-08-02987.1999","volume":"19","author":"T Nagayama","year":"1999","unstructured":"Nagayama T, Sinor AD, Simon RP et al (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987\u20132995","journal-title":"J Neurosci"},{"key":"8_CR84","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.1209200","volume":"334","author":"DK Nomura","year":"2011","unstructured":"Nomura DK, Morrison BE, Blankman JL et al (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334:809\u2013813","journal-title":"Science"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuroscience.2007.10.029","volume":"151","author":"E N\u00fa\u00f1ez","year":"2008","unstructured":"N\u00fa\u00f1ez E, Benito C, Tol\u00f3n RM et al (2008) Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are \u03b2-amyloid-linked events in Down\u2019s syndrome. Neuroscience 151:104\u2013110","journal-title":"Neuroscience"},{"key":"8_CR86","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.neulet.2010.03.026","volume":"474","author":"YT Oh","year":"2010","unstructured":"Oh YT, Lee JY, Lee J et al (2010) Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF\u03baB activation in BV2 murine microglial cells. Neurosci Lett 474:148\u2013153","journal-title":"Neurosci Lett"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","volume":"29C","author":"T Ohno-Shosaku","year":"2014","unstructured":"Ohno-Shosaku T, Kano M (2014) Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 29C:1\u20138","journal-title":"Curr Opin Neurobiol"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.plipres.2011.01.001","volume":"50","author":"P Pacher","year":"2011","unstructured":"Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50:193\u2013211","journal-title":"Prog Lipid Res"},{"key":"8_CR89","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"J Palazuelos","year":"2009","unstructured":"Palazuelos J, Aguado T, Pazos MR et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity. Brain 132:3152\u20133164","journal-title":"Brain"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/35097089","volume":"413","author":"D Panikashvili","year":"2001","unstructured":"Panikashvili D, Simeonidou C, Ben-Shabat S et al (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527\u2013531","journal-title":"Nature"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","volume":"71","author":"MR Pazos","year":"2013","unstructured":"Pazos MR, Mohammed N, Lafuente H et al (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT1A and CB2 receptors. Neuropharmacology 71:282\u2013291","journal-title":"Neuropharmacology"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215","journal-title":"Br J Pharmacol"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuroscience.2010.12.046","volume":"177","author":"S Petrosino","year":"2011","unstructured":"Petrosino S, M\u00e9nard B, Zs\u00fcrger N, Di Marzo V, Chabry J (2011) Alteration of the endocannabinoid system in mouse brain during prion disease. Neuroscience 177:292\u2013297","journal-title":"Neuroscience"},{"key":"8_CR94","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","volume":"51","author":"A Pintor","year":"2006","unstructured":"Pintor A, Tebano MT, Martire A et al (2006) The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51:1004\u20131012","journal-title":"Neuropharmacology"},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.celrep.2012.05.001","volume":"1","author":"JR Piro","year":"2012","unstructured":"Piro JR, Benjamin DI, Duerr JM et al (2012) A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer\u2019s disease. Cell Rep 1:617\u2013623","journal-title":"Cell Rep"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/ana.20462","volume":"57","author":"A Pisani","year":"2005","unstructured":"Pisani A, Fezza F, Galati S et al (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson\u2019s disease patients. Ann Neurol 57:777\u2013779","journal-title":"Ann Neurol"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","volume":"29","author":"DA Price","year":"2009","unstructured":"Price DA, Martinez AA, Seillier A et al (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Eur J Neurosci 29:2177\u20132186","journal-title":"Eur J Neurosci"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","volume":"25","author":"BG Ram\u00edrez","year":"2005","unstructured":"Ram\u00edrez BG, Bl\u00e1zquez C, G\u00f3mez del Pulgar T, Guzm\u00e1n M, de Ceballos ML (2005) Prevention of Alzheimer\u2019s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904\u20131913","journal-title":"J Neurosci"},{"key":"8_CR100","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/bph.12283","volume":"171","author":"C Rodr\u00edguez-Cueto","year":"2014","unstructured":"Rodr\u00edguez-Cueto C, Benito C, Fern\u00e1ndez-Ruiz J et al (2014a) Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br J Pharmacol 171:1472\u20131489","journal-title":"Br J Pharmacol"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000358127","volume":"81","author":"C Rodr\u00edguez-Cueto","year":"2014","unstructured":"Rodr\u00edguez-Cueto C, Benito C, Romero J et al (2014b) Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Pathobiology 81:149\u2013159","journal-title":"Pathobiology"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/ene.12350","volume":"21","author":"M Rossi","year":"2014","unstructured":"Rossi M, Perez-Lloret S, Doldan L et al (2014) Autosomal dominant cerebellar ataxias: a systematic review of clinical features. Eur J Neurol 21:607\u2013615","journal-title":"Eur J Neurol"},{"key":"8_CR103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-2094-8-5","volume":"8","author":"L Ruiz-Valdepe\u00f1as","year":"2011","unstructured":"Ruiz-Valdepe\u00f1as L, Mart\u00ednez-Orgado JA, Benito C et al (2011) Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J Neuroinflammation 8:5","journal-title":"J Neuroinflammation"},{"key":"8_CR104","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","volume":"26","author":"O Sagredo","year":"2007","unstructured":"Sagredo O, Ramos JA, Decio A, Mechoulam R, Fern\u00e1ndez-Ruiz J (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26:843\u2013851","journal-title":"Eur J Neurosci"},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/glia.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonz\u00e1lez S, Aroyo I et al (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease. Glia 57:1154\u20131167","journal-title":"Glia"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jnr.22682","volume":"89","author":"O Sagredo","year":"2011","unstructured":"Sagredo O, Pazos MR, Satta V et al (2011) Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease. J Neurosci Res 89:1509\u20131518","journal-title":"J Neurosci Res"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/157488912798842278","volume":"7","author":"O Sagredo","year":"2012","unstructured":"Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J (2012) Cannabinoids: novel medicines for the treatment of Huntington\u2019s disease. Recent Pat CNS Drug Discov 7:41\u201348","journal-title":"Recent Pat CNS Drug Discov"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/mds.26021","volume":"29","author":"C Sampaio","year":"2014","unstructured":"Sampaio C, Borowsky B, Reilmann R (2014) Clinical trials in Huntington\u2019s disease: interventions in early clinical development and newer methodological approaches. Mov Disord 29:1419\u20131428","journal-title":"Mov Disord"},{"key":"8_CR109","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1471-4159.2007.04668.x","volume":"102","author":"N Sang","year":"2007","unstructured":"Sang N, Zhang J, Chen C (2007) COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 102:1966\u20131977","journal-title":"J Neurochem"},{"key":"8_CR110","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ptr.5095","volume":"28","author":"C Scuderi","year":"2014","unstructured":"Scuderi C, Steardo L, Esposito G (2014) Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of \u03b2-amyloid expression in SHSY5YAPP+ cells through PPAR\u03b3 involvement. Phytother Res 28:1007\u20131013","journal-title":"Phytother Res"},{"key":"8_CR111","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/mol.54.3.459","volume":"54","author":"M Shen","year":"1998","unstructured":"Shen M, Thayer SA (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54:459\u2013462","journal-title":"Mol Pharmacol"},{"key":"8_CR112","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11481-009-9147-5","volume":"4","author":"WS Sheng","year":"2009","unstructured":"Sheng WS, Hu S, Ni HT, Rock RB, Peterson PK (2009) WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase. J Neuroimmune Pharmacol 4:244\u2013248","journal-title":"J Neuroimmune Pharmacol"},{"key":"8_CR113","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<211::AID-DDR3>3.0.CO;2-G","volume":"50","author":"E Shohami","year":"2000","unstructured":"Shohami E, Mechoulam R (2000) A non-psychotropic cannabinoid with neuroprotective properties. Drug Dev Res 50:211\u2013215","journal-title":"Drug Dev Res"},{"key":"8_CR115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-3565(24)39213-4","volume":"293","author":"SR Smith","year":"2000","unstructured":"Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293:136\u2013150","journal-title":"J Pharmacol Exp Ther"},{"key":"8_CR116","doi-asserted-by":"publisher","first-page":"538141","DOI":"10.1155\/2008\/538141","volume":"2008","author":"PF Stahel","year":"2008","unstructured":"Stahel PF, Smith WR, Bruchis J, Rabb CH (2008) Peroxisome proliferator-activated receptors: \u201ckey\u201d regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008:538141","journal-title":"PPAR Res"},{"key":"8_CR117","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/glia.20983","volume":"58","author":"N Stella","year":"2010","unstructured":"Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017\u20131030","journal-title":"Glia"},{"key":"8_CR118","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0033-1359314","volume":"33","author":"LT Takada","year":"2013","unstructured":"Takada LT, Geschwind MD (2013) Prion diseases. Semin Neurol 33:348\u2013356","journal-title":"Semin Neurol"},{"issue":"421","key":"8_CR119","first-page":"e1","volume":"33","author":"A Ternianov","year":"2012","unstructured":"Ternianov A, P\u00e9rez-Ortiz JM, Solesio ME et al (2012) Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol Aging 33(421):e1\u2013e16","journal-title":"Neurobiol Aging"},{"key":"8_CR120","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","volume":"1283","author":"RM Tol\u00f3n","year":"2009","unstructured":"Tol\u00f3n RM, N\u00fa\u00f1ez E, Pazos MR et al (2009) The activation of cannabinoid CB2 receptors stimulates in situ and in vitro \u03b2-amyloid removal by human macrophages. Brain Res 1283:148\u2013154","journal-title":"Brain Res"},{"key":"8_CR121","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/cn200114w","volume":"3","author":"S Valdeolivas","year":"2012","unstructured":"Valdeolivas S, Satta V, Pertwee RG, Fern\u00e1ndez-Ruiz J, Sagredo O (2012) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3:400\u2013406","journal-title":"ACS Chem Neurosci"},{"key":"8_CR122","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1038\/cddis.2013.387","volume":"4","author":"S Valdeolivas","year":"2013","unstructured":"Valdeolivas S, Pazos MR, Bisogno T et al (2013) The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis 4:e862","journal-title":"Cell Death Dis"},{"issue":"1","key":"8_CR123","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","volume":"12","author":"S Valdeolivas","year":"2014","unstructured":"Valdeolivas S, Navarrete C, Cantarero I et al (2014) Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12(1):185\u2013199","journal-title":"Neurotherapeutics"},{"key":"8_CR124","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1523\/JNEUROSCI.21-17-06475.2001","volume":"21","author":"M van der Stelt","year":"2001","unstructured":"van der Stelt M, Veldhuis WB, Bar PR et al (2001) Neuroprotection by \u03949-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21:6475\u20136579","journal-title":"J Neurosci"},{"key":"8_CR125","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00018-006-6037-3","volume":"63","author":"M van der Stelt","year":"2006","unstructured":"van der Stelt M, Mazzola C, Esposito G et al (2006) Endocannabinoids and \u03b2-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63:1410\u20131424","journal-title":"Cell Mol Life Sci"},{"key":"8_CR135","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2015.04.005","volume":"79","author":"C V\u00e1zquez","year":"2015","unstructured":"V\u00e1zquez C, Tol\u00f3n RM, Pazos MR et al (2015) Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: in vivo studies. Neurobiol Dis 79:41\u201350","journal-title":"Neurobiol Dis"},{"key":"8_CR126","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12017-014-8314-x","volume":"16","author":"E Vendel","year":"2014","unstructured":"Vendel E, de Lange EC (2014) Functions of the CB1 and CB2 receptors in neuroprotection at the level of the blood-brain barrier. Neuromolecular Med 16:620\u2013642","journal-title":"Neuromolecular Med"},{"key":"8_CR127","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","volume":"23","author":"L Walter","year":"2003","unstructured":"Walter L, Franklin A, Witting A et al (2003) Non-psychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398\u20131405","journal-title":"J Neurosci"},{"key":"8_CR128","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11427-013-4604-z","volume":"57","author":"Y Wang","year":"2014","unstructured":"Wang Y, Ma S, Wang Q et al (2014) Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. Sci China Life Sci 57:201\u2013208","journal-title":"Sci China Life Sci"},{"key":"8_CR130","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0306-4522(94)90511-8","volume":"63","author":"TM Westlake","year":"1994","unstructured":"Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer\u2019s brains. Neuroscience 63:637\u2013652","journal-title":"Neuroscience"},{"key":"8_CR131","doi-asserted-by":"publisher","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","volume":"32","author":"M Yamanaka","year":"2012","unstructured":"Yamanaka M, Ishikawa T, Griep A et al (2012) PPAR\u03b3\/RXR\u03b1-induced and CD36-mediated microglial amyloid-\u03b2 phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice. J Neurosci 32:17321\u201317331","journal-title":"J Neurosci"},{"key":"8_CR132","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55782\/ane-2012-1904","volume":"72","author":"M Ziemka-Na\u0142\u0119cz","year":"2012","unstructured":"Ziemka-Na\u0142\u0119cz M, Zalewska T (2012) Endogenous neurogenesis induced by ischemic brain injury or neurodegenerative diseases in adults. Acta Neurobiol Exp 72:309\u2013324","journal-title":"Acta Neurobiol Exp"}],"container-title":["Handbook of Experimental Pharmacology","Endocannabinoids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-20825-1_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:19:47Z","timestamp":1748636387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-20825-1_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319208244","9783319208251"],"references-count":123,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-20825-1_8","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}